IVERIC bio

company

About

IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$250M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2007
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:ISEE
Legal Name
IVERIC bio, Inc.
Also Known As
Ophthotech Corporation

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
10
$807.90M
IVERIC bio has raised a total of $807.90M in funding over 2 rounds. Their latest funding was raised on Nov 30, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 30, 2022 Post-IPO Equity $300M Detail
Jul 26, 2022 Post-IPO Debt $250M 2 Hercules Capital
Silicon Valley Bank
Detail
Jul 13, 2021 Post-IPO Equity $100.20M Detail
Jan 1, 2020 Post-IPO Equity 1 Detail
Jan 24, 2014 Post-IPO Equity $41.70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
5
8
IVERIC bio is funded by 8 investors. Hercules Capital and Silicon Valley Bank are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
Silicon Valley Bank Yes Post-IPO Debt
Sofinnova Investments Yes Series Unknown
Clarus Ventures Yes Series B
Frazier Healthcare Partners Post-IPO Equity
Novo Holdings Post-IPO Equity
HBM Healthcare Investments AG Series B
SV Health Investors Series B

Employee Profiles

Number of Employee Profiles
19
IVERIC bio has 19 current employee profiles, including Board member David Guyer
Board member
Executive
Executive
Executive
Executive